A Life-Changing Class of its Own
Utilizing the novel structural and functional properties of theta-defensins as a template to design OrynotidesTM , new therapeutic drug candidates to treat complex, difficult-to-treat diseases.
A Life-Changing Class of its Own
Utilizing the novel structural and functional properties of theta-defensins as a template to design OrynotidesTM, new therapeutic drug candidates to treat complex, difficult-to-treat diseases
Oryn Therapeutics
Oryn is introducing a paradigm changing approach to drug development with a revolutionary new class of therapeutics, Orynotides. The company’s mission is to improve quality of life by creating safer, more efficacious treatments for autoimmune and chronic inflammatory diseases, drug resistant infections, and cancer.
Orynotides: Therapeutic Benefit, Reduced Risk
Orynotides are a novel, patented class of therapeutics bioinspired by naturally occurring peptides discovered in non-human primates. Orynotides are safe and stable, exhibit low toxicity and low immunogenicity, and are easy to produce. Therapeutic applications include diseases for which current treatments have black box warnings and limited efficacy. Thus, Orynotides offer a new and revolutionary therapeutic approach for treatment of chronic and life-threatening diseases.
-
Highly Stable
-
Easy to Synthesize
-
Broad Range of Applications
-
Low Toxicity
-
Low Immunogenicity
-
Immunomodulatory
Therapeutic Areas
Orynotide ORYN 1001 is being developed as a novel treatment for rheumatoid arthritis, COVID-19, and other systemic inflammatory diseases. Other Orynotides are being developed for viral, bacterial, and fungal infections, inflammatory bowel disease, and cancer.
-
Autoimmune Diseases
-
Oncology
-
Chronic Inflammatory Disease
-
Infectious Disease
With the successful completion of our Phase 1B trial for the Treatment of Rheumatoid Arthritis (A Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD 1 in Rheumatoid Arthritis Patients with Mild Disease Managed with DMARDs), the systemic safety profile of the first Orynotide therapeutic drug candidate has been validated.
Leadership Team
Our goal is to become the leader in new therapeutic development to safely treat autoimmune and inflammatory diseases, infectious diseases, as well as combination immunotherapy for cancer treatment.
